Skip to main content
TiumBio Co., Ltd. logo

TiumBio Co., Ltd. — Investor Relations & Filings

Ticker · 321550 ISIN · KR7321550006 KO Professional, scientific and technical activities
Open in API
Filings indexed 296 across all filing types
Latest filing 2020-12-17 Director's Dealing
Country KR South Korea
Listing KO 321550

About TiumBio Co., Ltd.

http://www.tiumbio.com/en/

TiumBio is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for rare and incurable diseases. The company's pipeline targets conditions with high unmet medical needs, including fibrotic diseases, cancer, and rare hematological disorders. Its lead assets include Merigolix (TU2670), an oral GnRH antagonist in clinical development for endometriosis and uterine fibroids, and TU7710, a long-acting recombinant activated factor VII for hemophilia. TiumBio also develops small molecule antagonists targeting the TGF-β signaling pathway for applications in oncology and fibrosis. The company advances its programs through clinical development and strategic global partnerships.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the shareholding changes of a specific individual (Seo Jeong-min) at TiumBio. This is a standard regulatory filing for insider trading/shareholding changes by company executives, which corresponds to the 'Director's Dealing' category.
2020-12-17 Korean
주식매수선택권행사
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing from a Korean company (TiumBio) regarding the exercise of stock options (주식매수선택권행사). It details the number of shares exercised, the exercise price, the impact on total shares, and the schedule for new share listing. This falls under the category of capital changes resulting from the exercise of options, which is classified as a share issue/capital change.
2020-12-15 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory notice regarding the suspension of share registration (closing of the shareholder register) for the purpose of determining shareholders for an upcoming Annual General Meeting. It does not contain the full report or proxy materials, but rather serves as a formal regulatory announcement of a corporate action. Given it does not fit into specific categories like dividend announcements or share buybacks, it falls under the general regulatory filing category.
2020-12-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a standard Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a mandatory disclosure filed with the Financial Supervisory Service (FSS) and the Korea Exchange (KRX) when a director or major shareholder changes their shareholding position. This specific type of filing is categorized as 'Director's Dealing' (DIRS) in the provided schema, as it details personal share transactions and ownership status of company insiders.
2020-12-01 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (FSS) and the Korea Exchange. This type of filing is a mandatory disclosure by company insiders (directors/executives) regarding their personal share transactions or changes in ownership. In the provided taxonomy, this corresponds to 'Director's Dealing' (DIRS), which covers insider trades and ownership reports by company executives.
2020-12-01 Korean
투자판단관련주요경영사항(자궁내막증 치료제 TU2670의 임상 2a상 시험 계획 승인)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from the Korea Exchange (KRX) system (KIND) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It details the approval of a Phase 2a clinical trial for a drug (TU2670). Since this is a specific regulatory disclosure of a material event (clinical trial approval) rather than a general report or a report announcement, it falls under the 'Regulatory Filings' category as the most appropriate classification for miscellaneous corporate disclosures that do not fit into specific financial report categories.
2020-11-24 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.